Kura Oncology (KURA) Non-Current Debt (2014 - 2026)
Kura Oncology (KURA) posted quarterly Non-Current Debt of $9.7 million for Q1 2026, up 27.44% year-over-year from $7.6 million in Q1 2025, and little changed quarter-over-quarter from $9.7 million in Q4 2025.
Kura Oncology (KURA) Non-Current Debt (2014 - 2026) Analysis & Trends
Kura Oncology (KURA) has reported Non-Current Debt for 12 consecutive years, with $9.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Debt rose 27.44% year-over-year to $9.7 million; the TTM figure through Mar 2026 stood at $9.7 million (up 27.44% YoY), while the FY2025 annual figure was $9.7 million, up 40.41% from the prior year.
- Non-Current Debt was little changed at $9.7 million in Q1 2026 per KURA's latest filing, from $9.7 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $9.7 million in Q1 2026 and bottomed at $5.3 million in Q3 2025.
- Historically, Non-Current Debt has averaged $8.4 million across 5 years, with a median of $9.2 million in 2022.
- On a YoY basis, Non-Current Debt climbed as much as 40.41% in 2025 and fell as far as 31.21% in 2025.
- Kura Oncology's Non-Current Debt stood at $9.2 million in 2022, then gained by 1.9% to $9.3 million in 2023, then retreated by 25.89% to $6.9 million in 2024, then surged by 40.41% to $9.7 million in 2025, then gained by 0.39% to $9.7 million in 2026.
- Business Quant data shows KURA's Non-Current Debt at $9.7 million in Q1 2026, $9.7 million in Q4 2025, and $5.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Kura Oncology | 966.11 Mn | 966.11 Mn | 20.63 Mn | 5.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.57 Mn |
| Mar 31, 2026 | 9.75 Mn |
| Dec 31, 2025 | 9.71 Mn |
| Sep 30, 2025 | 5.34 Mn |
| Jun 30, 2025 | 6.51 Mn |
| Mar 31, 2025 | 7.65 Mn |
| Dec 31, 2024 | 6.92 Mn |
| Sep 30, 2024 | 7.76 Mn |
| Jun 30, 2024 | 8.58 Mn |
| Mar 31, 2024 | 9.38 Mn |
| Dec 31, 2023 | 9.33 Mn |
| Sep 30, 2023 | 9.29 Mn |
| Jun 30, 2023 | 9.24 Mn |
| Mar 31, 2023 | 9.20 Mn |
| Dec 31, 2022 | 9.16 Mn |
| Mar 31, 2021 | 3.50 Mn |
| Dec 31, 2020 | 4.25 Mn |
| Sep 30, 2020 | 5.00 Mn |
| Jun 30, 2020 | 5.75 Mn |
| Mar 31, 2020 | 6.50 Mn |